Lipocine Net Worth
Lipocine Net Worth Breakdown | LPCN |
Lipocine Net Worth Analysis
Lipocine's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Lipocine's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Lipocine's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Lipocine's net worth analysis. One common approach is to calculate Lipocine's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Lipocine's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Lipocine's net worth. This approach calculates the present value of Lipocine's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Lipocine's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Lipocine's net worth. This involves comparing Lipocine's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Lipocine's net worth relative to its peers.
Enterprise Value |
|
To determine if Lipocine is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lipocine's net worth research are outlined below:
| Lipocine generated a negative expected return over the last 90 days | |
| Lipocine has high historical volatility and very poor performance | |
| Net Loss for the year was (16.35 M) with profit before overhead, payroll, taxes, and interest of 4.8 M. | |
| Lipocine currently holds about 37.4 M in cash with (11.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.42. | |
| Lipocine has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Disposition of 5000 shares by Higuchi John W. of Lipocine at 1.3534 subject to Rule 16b-3 |
Lipocine uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lipocine. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lipocine's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Lipocine's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lipocine is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lipocine backward and forwards among themselves. Lipocine's institutional investor refers to the entity that pools money to purchase Lipocine's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Caldwell Sutter Capital Inc | 2024-09-30 | 471 | Group One Trading, Lp | 2024-09-30 | 423 | Advisor Group Holdings, Inc. | 2024-09-30 | 227 | Hartland & Co | 2024-09-30 | 74.0 | Tidemark Llc | 2024-09-30 | 59.0 | Bank Of America Corp | 2024-09-30 | 56.0 | Jpmorgan Chase & Co | 2024-09-30 | 12.0 | Royal Bank Of Canada | 2024-06-30 | 9.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 221.5 K | Blackrock Inc | 2024-09-30 | 89.3 K |
Follow Lipocine's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 23.91 M.Market Cap |
|
Project Lipocine's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.82) | (0.78) | |
| Return On Capital Employed | (0.79) | (0.83) | |
| Return On Assets | (0.82) | (0.78) | |
| Return On Equity | (0.72) | (0.76) |
When accessing Lipocine's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Lipocine's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lipocine's profitability and make more informed investment decisions.
Evaluate Lipocine's management efficiency
Lipocine has return on total asset (ROA) of (0.2267) % which means that it has lost $0.2267 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3412) %, meaning that it created substantial loss on money invested by shareholders. Lipocine's management efficiency ratios could be used to measure how well Lipocine manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of January 2025, Return On Tangible Assets is likely to grow to -0.78. In addition to that, Return On Capital Employed is likely to drop to -0.83. At this time, Lipocine's Total Assets are very stable compared to the past year. As of the 30th of January 2025, Other Assets is likely to grow to about 4 M, while Net Tangible Assets are likely to drop about 27 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.45 | 4.22 | |
| Tangible Book Value Per Share | 4.45 | 4.22 | |
| Enterprise Value Over EBITDA | (0.55) | (0.58) | |
| Price Book Value Ratio | 0.65 | 0.68 | |
| Enterprise Value Multiple | (0.55) | (0.58) | |
| Price Fair Value | 0.65 | 0.68 | |
| Enterprise Value | 11.4 M | 10.9 M |
Lipocine showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 0.5152 | Revenue | Quarterly Revenue Growth 137.519 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lipocine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lipocine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lipocine insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lipocine Corporate Filings
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 7th of August 2024 An amendment to a previously filed Form 8-K | ViewVerify |
Lipocine Earnings per Share Projection vs Actual
Lipocine Corporate Management
| CPA CPA | Co Sec | Profile | |
| Logan Morse | Marketing Sales | Profile | |
| Nachiappan Chidambaram | Senior Development | Profile | |
| M MD | Chief Director | Profile | |
| Krista Fogarty | Principal Controller | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.75) | Revenue Per Share | Quarterly Revenue Growth 137.519 | Return On Assets | Return On Equity |
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.